Acipimox

Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].

Product Specifications

CAS Number

[51037-30-0]

Product Name Alternative

K-9321

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Acipimox.html

Purity

99.58

Solubility

DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic)

Smiles

O=C(C1=C[N+]([O-])=C(C)C=N1)O

Molecular Formula

C6H6N2O3

Molecular Weight

154.13

Precautions

H302, H315, H319, H335

References & Citations

[1]Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83 (12) :2671-2677.|[2]Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174 (2) :267-72.|[3]Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171 (2) :161-7.